Abstract | BACKGROUND: METHODS: A correlation of TNF-α expression with the prognosis was analyzed in 62 HCC patients who underwent surgical resection and subsequent received adjuvant sorafenib treatment. The relation of TNF-α expression and sorafenib sensitivity was determined in different HCC cell lines. The combined therapeutic effects of sorafenib and ulinastatin, which could inhibit TNF-α expression, on HCC were examined in vitro and in vivo. FINDINGS: High TNF-α expression was correlated with poor outcomes in HCC patients who received adjuvant sorafenib after surgery. In vitro experiments showed that TNF-α promotes HCC cell resistant to sorafenib through inducing epithelial-mesenchymal transition (EMT). Notably, the current study revealed that sorafenib has no significant influence on the expression and secretion of TNF-α, and sorafenib had limited effectiveness on reversing EMT in HCC cells with high TNF-α expression. Inhibiting the expression of TNF-α with ulinastatin significantly enhanced the anti- tumor effect of sorafenib on HCC cells with high expression of TNF-α in vitro and in vivo. INTERPRETATION: Our findings indicate that TNF-α may serve as a novel predictor of sorafenib sensitivity in HCC patients. Sorafenib combined with ulinastatin may improve the effectiveness of treatment of HCC in patients with high expression of TNF-α. FUND: This work was supported by grants from the National Natural Science Foundation of China (no.81572398; no.81672419), the Science and Technology Planning Project of Guangdong Province (no. 2017A010105003; no.2015A050502023; no.2016A020216010), and the Natural Science Foundation of Guangdong Province (no.2014A030313061; no. 2013B021800101).
|
Authors | Wenliang Tan, Xuan Luo, Wenda Li, Jinyi Zhong, Jun Cao, Sicong Zhu, Xianqing Chen, Rui Zhou, Changzhen Shang, Yajin Chen |
Journal | EBioMedicine
(EBioMedicine)
Vol. 40
Pg. 446-456
(Feb 2019)
ISSN: 2352-3964 [Electronic] Netherlands |
PMID | 30594557
(Publication Type: Journal Article)
|
Copyright | Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Glycoproteins
- Protein Kinase Inhibitors
- Tumor Necrosis Factor-alpha
- Sorafenib
- urinastatin
|
Topics |
- Animals
- Carcinoma, Hepatocellular
(drug therapy, metabolism, mortality, pathology)
- Cell Line, Tumor
- Disease Models, Animal
- Drug Resistance, Neoplasm
- Epithelial-Mesenchymal Transition
(drug effects)
- Female
- Gene Expression Regulation, Neoplastic
(drug effects)
- Glycoproteins
(pharmacology)
- Humans
- Liver Neoplasms
(drug therapy, metabolism, mortality, pathology)
- Mice
- Models, Biological
- Protein Kinase Inhibitors
(pharmacology, therapeutic use)
- Sorafenib
(pharmacology, therapeutic use)
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors, genetics, metabolism)
- Xenograft Model Antitumor Assays
|